Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Englumafusp alfa

Generic Name: Englumafusp alfa

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1

Recruiting

Posted: 2019/09/04

Sponsor:Hoffmann-La Roche

ID:NCT04077723

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Roche Highlights Encouraging Long-Term Data in Hematological Disorders at ASH 2024

7 months ago

Roche will present over 40 abstracts at ASH 2024, showcasing advancements in lymphoma treatment with Polivy, Lunsumio, and Columvi, demonstrating its commitment to improving patient outcomes.

Genentech Presents Encouraging Long-Term Data for Lymphoma and Hemophilia Treatments

7 months ago

Genentech's Polivy, in combination with R-CHP, demonstrates sustained benefits in diffuse large B-cell lymphoma (DLBCL) after five years.

Bispecific Antibodies: Promising Advances Amid Adoption Challenges in Cancer Treatment

a year ago

Bispecific antibodies represent a significant advancement in cancer immunotherapy, targeting both tumor antigens and immune cells to enhance cytotoxicity without requiring patient-derived cells like CAR-T therapy.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy